Skip directly to content

Areas of research eligible for the programme

Areas of research eligible for ERISTA 2018

Advance the understanding of the use of apixaban* in patients with non-valvular atrial fibrillation (NVAF) in specific populations at elevated risk and unmet need

May include but are not limited to: 

  • Patients undergoing surgical interventions or cardiac procedures, patients with renal impairment, elderly or frail patients, patients with extreme body weights, patients experiencing bleeding while on anticoagulant therapy

 

Advance the understanding of the use of apixaban* in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and in the prevention of recurrent DVT and PE in populations at elevated risk and unmet need

May include but are not limited to: 

  • Patients in need of extended venous thromboembolism (VTE) treatment, specific patient populations such as patients with Superficial Venous Thrombosis (SVT) / Distal Venous Thrombosis, patients with renal impairment, elderly or frail patients, patients with extreme body weights, patients experiencing bleeding while on anticoagulant therapy

 

Optimise patient care in the above indications and the translation of scientific evidence into clinical practice. These may include:

  • Comparative research to assess the impact of educational tools or multidisciplinary approaches to improve the use of apixaban* and patient follow up, as evaluated by eg patient reported outcomes, patient satisfaction, patient preferences and quality of life

 

*Proposals that will generate data on anticoagulants in addition to apixaban are acceptable. However, at least in part each project should aim to generate data which increases understanding of the use of apixaban.

This site is intended for the use of investigators considering a submission or intending to submit to the ERISTA program. It is NOT intended to provide product information.